Article Information
History
- May 17, 2021.
Article Versions
- You are currently viewing Version 1 of this article (May 17, 2021 - 11:07).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Jéromine Klingler1,2,
- Gregory S. Lambert1,
- Vincenza Itri1,
- Sean Liu1,
- Juan C. Bandres1,2,
- Gospel Enyindah-Asonye1,
- Xiaomei Liu1,2,
- Kasopefoluwa Y. Oguntuyo3,
- Fatima Amanat3,4,
- Benhur Lee3,
- Susan Zolla-Pazner1,3,
- Chitra Upadhyay1 and
- Catarina E. Hioe1,2,3,*
- 1Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY USA
- 2James J. Peters VA Medical Center, Bronx, NY, USA
- 3Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 4Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ↵*Corresponding author Contact: catarina.hioe{at}mssm.edu, catarina.hioe{at}va.gov
Posted May 17, 2021.
SARS-CoV-2 mRNA vaccines induce a greater array of spike-specific antibody isotypes with more potent complement binding capacity than natural infection
